Press coverage about Epirus Biopharmaceuticals (NASDAQ:EPRS) has been trending positive on Thursday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Epirus Biopharmaceuticals earned a news impact score of 0.35 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.2385164949183 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.watchlistnews.com/epirus-biopharmaceuticals-eprs-receives-daily-media-sentiment-score-of-0-35/1674355.html.

About Epirus Biopharmaceuticals

Insider Buying and Selling by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.